Skip to main content

Tropicamide (Monograph)

Brand names: Mydral, Mydriacyl, Tropicacyl
Drug class: Mydriatics
ATC class: S01FA06
VA class: OP600
Chemical name: Benzeneacetamide, N-ethyl-α-(hydroxymethyl)-N-(4-pyridinylmethyl)-
Molecular formula: C17H20N2O2
CAS number: 1508-75-4

Introduction

Mydriatic and cycloplegic; synthetic tertiary amine antimuscarinic.

Uses for Tropicamide

Ophthalmologic Examination

Used to produce mydriasis and cycloplegia prior to diagnostic procedures (e.g., examination of the fundus).

Efficacy may differ slightly in patients with light and dark irides (see Dosage under Dosage and Administration and see Actions).

Used in fixed-combination with hydroxyamphetamine hydrobromide when a short period of mydriasis or only partial cycloplegia is preferred.

Tropicamide Dosage and Administration

General

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution.

For ophthalmic use only; not for injection.

Avoid contamination of the solution container.

To avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 2–3 minutes after topical instillation of tropicamide.

Dosage

In patients with heavily pigmented irides, higher tropicamide concentrations may be required.

Solution concentrations of 0.5 and 1% produce mydriasis; the 1% concentration also produces cycloplegia. The 0.5% concentration may be useful for producing mydriasis with only slight cycloplegia.

Pediatric Patients

Ophthalmologic Examination
Mydriasis with Minimal Cycloplegia (e.g., for Fundus Examination)
Ophthalmic

1 or 2 drops of a 0.5% solution into the eye(s) 15–20 minutes before examination.

Tropicamide 0.25% in fixed combination with hydroxyamphetamine hydrobromide 1%: 1 or 2 drops into the conjunctival sac of the eye(s).

Cycloplegia for Refraction
Ophthalmic

1 or 2 drops of a 1% solution into the eye(s); repeat in 5 minutes. Perform the examination within 30 minutes after the second instillation. If patient is not examined within 20–30 minutes, instill an additional drop of the 1% solution.

Adults

Ophthalmologic Examination
Mydriasis with Minimal Cycloplegia (e.g., for Fundus Examination)
Ophthalmic

1 or 2 drops of a 0.5% solution into the eye(s) 15–20 minutes before examination.

Tropicamide 0.25% in fixed combination with hydroxyamphetamine hydrobromide 1%: 1 or 2 drops into the conjunctival sac of the eye(s).

Cycloplegia for Refraction
Ophthalmic

1 or 2 drops of a 1% solution into the eye(s); repeat in 5 minutes. Perform the examination within 30 minutes after the second instillation. If patient is not examined within 20–30 minutes, instill an additional drop of the 1% solution.

Special Populations

Tropicamide alone or in fixed combination with hydroxyamphetamine hydrobromide: No special population dosage recommendations at this time.

Cautions for Tropicamide

Contraindications

Warnings/Precautions

Warnings

CNS Effects

Risk of CNS disturbances, including psychotic reactions and behavioral disturbances; may be dangerous in pediatric patients (see Pediatric Use under Cautions).

Intraocular Pressure

Mydriatics may cause a transient increase in IOP. Consider the possibility of undiagnosed glaucoma in some patients. (See Contraindications.)

Sensitivity Reactions

Anticholinergic Sensitivity

Consider risk of psychotic reactions and behavioral disturbances in patients who are hypersensitive to anticholinergic drugs. (See CNS Effects and also Pediatric Use under Cautions.)

General Precautions

Use of Fixed Combinations

When tropicamide is used in fixed combination with hydroxyamphetamine hydrobromide, consider the cautions, precautions, and contraindications associated with hydroxyamphetamine hydrobromide.

Concomitant Diseases

When tropicamide is used in fixed combination with hydroxyamphetamine hydrobromide, closely monitor patients with hypertension, hyperthyroidism, diabetes mellitus, cardiac disorders (i.e., arrhythmias, chronic ischemic heart disease), glaucoma, or increased IOP following topical application.

Specific Populations

Pregnancy

Category C.

Lactation

Not known if tropicamide is distributed into milk. Exercise caution if used in nursing women.

Pediatric Use

May rarely cause potentially dangerous CNS disturbances in pediatric patients. (See CNS Effects under Cautions.)

Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported in pediatric patients with use of anticholinergic agents.

Tropicamide/hydroxyamphetamine fixed combination: Safety and efficacy not established.

Geriatric Use

Tropicamide: No overall differences in safety and efficacy relative to younger adults.

Tropicamide/hydroxyamphetamine fixed combination: No overall differences in safety and efficacy relative to younger adults. Consider possibility of undiagnosed glaucoma in geriatric patients. Monitor geriatric patients closely following topical application since glaucoma or increased IOP may be precipitated in these patients. (See Contraindications.)

Common Adverse Effects

Ocular: Increased IOP, transient stinging, blurred vision, superficial punctate keratitis, photophobia.

Systemic: Mouth dryness, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, CNS disturbances, muscle rigidity.

Drug Interactions

Specific Drugs

Drug

Interaction

Carbachol

Tropicamide may interfere with ocular antihypertensive action of carbachol

Cholinesterase inhibitors (ophthalmic)

Tropicamide may interfere with ocular antihypertensive action of ophthalmic cholinesterase inhibitors

Pilocarpine

Tropicamide may interfere with ocular antihypertensive action of pilocarpine

Tropicamide Pharmacokinetics

Absorption

Onset

Tropicamide: Maximum mydriatic effect appears in about 20–40 minutes.

Tropicamide: Maximum cycloplegia occurs within 20–35 minutes.

Tropicamide/hydroxyamphetamine fixed combination: Mydriasis occurs within 15 minutes and peaks in about 60 minutes.

Duration

Tropicamide: Mydriatic effects last about 6–7 hours; however, complete recovery from mydriasis may require up to 24 hours in some individuals.

Tropicamide: Cycloplegia persists for 50 minutes to 6 hours.

Tropicamide/hydroxyamphetamine: Mydriasis, inhibition of pupillary light response, and partial cycloplegia generally last for about 3 hours; recovery begins in about 90 minutes, and total recovery usually occurs in 6–8 hours. However, recovery may require up to 24 hours in some individuals. Patients with light irides may experience slightly greater mydriasis than patients with dark irides.

Distribution

Extent

Not known if tropicamide is distributed into milk.

Stability

Storage

Ophthalmic

Solution

Tightly closed containers at 8–27°C. Avoid excessive heat. Do not refrigerate.

Tropicamide/hydroxyamphetamine: 20–25°C. Protect from light.

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Tropicamide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Solution

0.5%*

Mydral

OCuSOFT

Mydriacyl (with benzalkonium chloride)

Alcon

Tropicacyl (with benzalkonium chloride)

Akorn

Tropicamide Ophthalmic Solution (with benzalkonium chloride)

Bausch & Lomb

1%*

Mydral

OCuSOFT

Mydriacyl (with benzalkonium chloride)

Alcon

Tropicacyl (with benzalkonium chloride)

Akorn

Tropicamide Ophthalmic Solution (with benzalkonium chloride)

Bausch & Lomb

Tropicamide Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Solution

0.25% with Hydroxyamphetamine Hydrobromide 1%

Paremyd (with benzalkonium chloride)

Akorn

AHFS DI Essentials™. © Copyright 2024, Selected Revisions August 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

Reload page with references included